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A glimpse of the ERM proteins
Godwin A. Ponuwei1,2
Abstract
In all eukaryotes, the plasma membrane is critically important as it maintains the architectural integrity of the cell.
Proper anchorage and interaction between the plasma membrane and the cytoskeleton is critical for normal
cellular processes. The ERM (ezrin-radixin-moesin) proteins are a class of highly homologous proteins involved in
linking the plasma membrane to the cortical actin cytoskeleton. This review takes a succinct look at the biology of
the ERM proteins including their structure and function. Current reports on their regulation that leads to activation
and deactivation was examined before taking a look at the different interacting partners. Finally, emerging roles of
each of the ERM family members in cancer was highlighted.
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Review
The ERM proteins are evolutionary conserved group of
three related proteins (ezrin, radixin and moesin) that
possess band Four point one (4.1) as a common origin
[1]. They interact with the plasma membrane through
a common FERM (Four point one, ERM) domain [2].
The ERM proteins are located in cellular structures
such as filopodia, lamellipodia, apical microvilli, ruf-
fling membranes, cleavage furrow of mitotic cells, re-
traction fibres, and adhesion sites, where the plasma
membrane interacts with F-actin [3]. ERMs are crit-
ical for structural stability and for maintaining the in-
tegrity of the cell cortex by coupling transmembrane
proteins to the actin cytoskeleton [1]. These proteins
also play very pivotal intracellular scaffolding roles
that aid signal transduction between the intracellular
and extracellular compartments of the cell as well as
interacting with other membrane phospholipids [4].
Thus, ERMs are involved in regulating several cellu-
lar processes including reorganization of actin cyto-
skeleton, cell survival, membrane dynamics, cell
migration, adhesion and regulation of membrane
protrusion [4, 5].
Background
Structure of ERM proteins
Structurally, at the amino terminus of ERM proteins is
an approximately 1-296 amino acid FERM domain also
known as N-terminal ERM association domain (N-
ERMAD) through which they interact with cell mem-
branes. X-ray crystallography revealed that the FERM
domain consists of F1, F2 and F3, also respectively re-
ferred to as A, B and C subdomains that fold and joined
together to form an cloverleaf structure, and these sub-
domains are homologous to ubiquitin, acyl-CoA binding
protein and plekstrin homology domains respectively
[4, 5] (Fig. 1). The FERM region is closely flanked by a
central (approximately 200 amino acid) α–helical domain
that form coiled coils [4] and mediate interaction with pro-
tein kinase A (PKA) [6]. The carboxylic terminal tail con-
sists of 107 residues, and this terminus contains the F-actin
binding site through which ERMs interact with the actin
cytoskeleton [7]. In all ERM family members, distinct do-
mains within the N-terminal head and C-terminal tail
known as N- and C-ezrin-radixin-moesin association do-
mains (N-ERMAD and C-ERMAD respectively) mediates
homotypic and heterotypic head-to-tail interaction [4, 8, 9].
The N-ERMAD is distinct from the C-ERMAD in that it
is a labile domain that is inactivated by chemical agents
such as sodium dodecyl sulfate (SDS) treatment, and its
activity is negatively affected by freeze thawing, whereas
the C-ERMAD is unaffected by chemical treatment [10].
ERMs exist in a dormant, inactive closed conformation
within the cytosol in which the C-ERMAD stretches
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from the F-actin binding site through F2 and F3 to part
of the FERM region, thereby concealing both the F-actin
and the membrane binding sites from other binding
partners [7, 10, 11]. This covering of FERM by the C-
ERMAD is bolstered by the central α-helical domain in
that it binds the FERM domain to facilitate masking of
both domains [4]. Activation of ERMs requires opening
up the binding sites in the FERM domain and those of
the F-actin biding sites in the C-terminal domain. This
is achieved by phosphatidylinositol 4,5-bisphosphate
(PIP2)-mediated uncoupling of the C-terminal domain
from the FERM domain [1].
Regulation of ERM proteins
ERM proteins function is regulated by a two-step
process of open (active) and closed (inactive) conform-
ation [12]. They are mainly regulated through conform-
ational changes induced by phospholipids and kinases-
mediated phosphorylation, and this results in activation
of the proteins [13]. Recruitment of ERMs to areas of
the plasma membrane containing high amount of phos-
phoinositides such as PIP2 exposes a conserved regula-
tory threonine phosphorylation residue (T567, T564 and
T558 in ezrin, radixin and moesin respectively) located
in the C-ERMAD domain [14], and this induces a suc-
cessive activation mechanism whereby PIP2 first bind to
a subdomain in the N-terminal FERM domain followed
by plasma membrane translocation and phosphorylation
of the threonine residues [15]. There are three lysine-
rich consensus sites known to bind phosphoinositides
on the FERM domain of ERM proteins and mutation on
any of these sites inhibited PIP2-ERM interaction and
translocation to the plasma membrane [16]. PIP2-medi-
ated recruitment of ERMs to the plasma membrane is
sufficient not only in the phosphorylation of these pro-
teins by other kinases, but also in the formation of
microvilli [17].
Phosphorylation of the conserved threonine residue
can be induced by different signaling protein kinases
such as Rho-associated protein kinase (ROCK), myo-
tonic dystrophy kinase-related Cdc42-binding kinase,
G-protein coupled receptor kinase 2, Nck interacting
kinase [14, 18–20], protein kinase C (PKCα, PKCβ),
NFкB-inducing kinase (NIK), lymphocyte-oriented kin-
ase (LOK) thereby creating stearic hindrance that keeps
the FERM and C-ERMAD domains apart [11, 21–23], and
this stabilizes the active state of ERM proteins in their
open conformation [15, 17]. Ezrin can be phosphorylated
by cyclic-dependent kinase 5 (CDK5) on threonine 235
which lies between the FERM and C-ERMAD domains,
and mutation of this site facilitated ezrin localization to
plasma membrane [24].
Binding of ERM proteins to the cytoskeleton in many
cases is strengthened by phosphorylation of the proteins
[25]. Activation of the small Rho GTPase, RhoA and not
Rac or Cdc42 was able to induce phosphorylation of
both radixin and moesin, and this paralleled formation
of membrane protrusions in Swiss 3 T3 cells [26]. Also
upon activation of platelets with thrombin, the phos-
phorylation status of moesin on threonine 558 (a residue
also phosphorylated by PKCθ) was enhanced and this
bolstered the interaction of moesin with the cytoskel-
eton, and moesin was found localized at the spreading
filopodia [27]. Phosphorylation of radixin on threonine
564 at the C-terminal half by Rho-kinase had no effect
on the C-ERMAD to bind F-actin, but attenuated the
ability of the C-ERMAD to bind N-ERMAD [28] suggest-
ing that the activated state of ERM proteins during which
the intramolecular interaction between the N- and C- ter-
minal domains is inhibited, can be sustained by the phos-
phorylation of threonine 564 in radixin [25], threonines
558 and 567 in moesin and ezrin respectively [29].
ERM proteins can also be phosphorylated by receptor
tyrosine kinases. Epidermal growth factor (EGF) receptor
can phosphorylate ezrin at tyrosines 145 and 353 (Y145
and Y353) [30]. In epithelial kidney cells, Y353 phos-
phorylation is required for not only binding of phos-
phatidylinositol 3-kinase to ezrin, but for the activation
of Akt signaling pathway [31]. Similarly, stimulation of
ezrin-transfected LLC-PK1 cells with hepatocyte growth
factor (HGF) resulted in increased phosphorylation of
ezrin at the same tyrosine residues and this not only
promoted cell migration, but also enhanced intracellular
signal transduction [32]. Ezrin Y145 phosphorylation
was demonstrated in Jurkat T-cells expressing Lck (a Src
family kinase), but not in Lck-deficient cells [33].
Fig. 1 Basic Structure of ERM Proteins. All ERM proteins possess similar domain structure with the N terminus having F1, F2 and F3 subdomains.
At the central portion of the protein is an α-helical domain which is followed by a linker region. At the last 30 carboxyl terminal end is the F-actin
binding site
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It is now known that ERM proteins are also activated
by sphingolipids. For instance in several cell lines such
as A549, HEK, MEF, MCF7 and MDA cells, expression
of the bioactive sphingolipid, sphingosine-1-phosphate
(S1P) both endogenously and exogenously resulted in
phosphorylation and activation of ezrin in a time- and
dose-dependent manner [34, 35], and in Hela cells, S1P-
mediated phosphorylation was found to be through S1P
receptor 2 (S1PR2). This was required for filopodia for-
mation [34]. In a PKC-dependent manner, S1P stimula-
tion of pulmonary endothelial cells resulted in activation
of ezrin and moesin, but not radixin [36, 37]. However,
contrary to its known functions, via unclear mecha-
nisms, S1P phosphorylation of ezrin resulted in inhib-
ition of cell invasion, and this could be attributed to the
ability of S1P to act on different receptors [35]. In Hela
cells, generation of plasma membrane ceramide through
breakdown of sphingomyelin by the action of sphingo-
myelinase resulted in dephosphorylation of ERM pro-
teins, while decreasing plasma membrane levels of the
sphingolipid resulted in ERM proteins hyperphosphory-
lation [12].
Regulation of ERM proteins is also brought about by
dephosphorylation and inactivation of the proteins
through the activities of phosphatases, and via PIP2 hy-
drolysis. In Hela cells, ceramide drives ERM dephos-
phorylation through activation of protein phosphatase
1α (PP1α) with the resultant effect of inactivating ERM
and subsequent dissociation from the plasma membrane
[38]. Similarly, overexpression of the small protein tyro-
sine phosphatase, phosphatase of regenerating liver-3
(PRL-3) in HCT116 colon cancer cell line resulted in de-
phosphorylation of ezrin [39]. Moesin can be downregu-
lated by myosin light chain phosphatase through
dephosphorylation of threonine 558 [40]. Although, in
phorbol 12-myristate 13 acetate (PMA)-stimulated leu-
cocytes, ezrin is inactivated through calpain-mediated
cleavage, moesin and radixin are insensitive to cleavage
by calpain [41] suggesting that distinct regulatory mech-
anisms exist for each protein in the same cell.
Interaction of ERMs with other proteins
There are several proteins within the plasma membrane
that interact with activated ERM proteins through the
FERM domain. In a manner dependent on PIP2, ERM
proteins can associate with the cytoplasmic tails of intra-
cellular adhesion molecules -1, -3 (ICAM-1 and -3) [42]
and -2 (ICAM-2), as well as the hyaluronan receptor
CD44 and CD43 [43]. ERMs are also known to bind
PDZ (postsynaptic density protein)-containing proteins
such as transporters and ion channels through other an-
choring proteins like NHERF1 (Na+-H+ exchanger regula-
tory factor) also known as ERM-binding phosphoprotein
50 (EBP50) and NHERF2 [44, 45]. They also interact with
membrane glycoproteins such as P-selectin glycoprotein
ligand-1 which tether white blood cells to injured tissues
[42]. The α-helical domain on the central portion of ERMs
can also bind subunits of HOPS complex (homotypic fu-
sion and protein sorting) as well as the regulatory subunits
RII of protein kinase A [46]. Binding of ERM proteins to
PKA tethers it to downstream targets to effect cAMP-
mediated biological processes such as cell differentiation,
proliferation, metabolism, apoptosis, exocytosis, T cell and
B cell activation, muscle contraction [6]. In COS-1 cells,
ezrin was shown to bind and link syndecan-2 to the cor-
tical cytoskeleton [47]. The death receptor Fas/CD95,
unlike other membrane proteins that bind all ERM pro-
teins, did not bind to moesin but only to ezrin in T lym-
phocytes [48].
ERM proteins and cancer
Cancer cell migration is a coordinated process involving
different steps that bring about loss of cell-cell adhesion
and deregulation of cell-matrix interaction. Several re-
ports have outlined different factors such as localization
of ERMs within the cell, their level of phosphorylation
as well as expression profile to be responsible for ERM
proteins-mediated promotion of tumourigenesis [2].
Below is a brief discussion of each of the ERM proteins,
with the aim of highlighting their significance in differ-
ent human cancers.
Ezrin
Abnormal localization of ERM proteins is a leading fac-
tor resulting aberrant intracellular signal transduction
triggered by growth factors. For instance, in breast car-
cinoma, ezrin which was originally situated at apical
structures in normal cell was found translocated to the
cytoplasm and plasma membrane and this aberrant
localization resulted in the acquisition of an epithelial-
mesenchymal transition (EMT) in which cells loss their
normal differentiated, planar and apical-based polarity
and anchorage dependent architecture and instead ac-
quire metastatic phenotype that correlated with poor
prognosis [49].
In epithelial cells, interaction of ezrin with Fes kinase
causes recruitment and activation of the later at the cell
membrane where it facilitates HGF-mediated loss of
cell-cell and cell-ECM contacts resulting in cell migra-
tion as revealed by wound healing assay [32, 50]. In this
interaction, ezrin not only localized to the leading edge
of migrating epithelial cells [50], but also promoted the
formation of membrane protrusions [2].
Similarly, upon phosphorylation of the ERM proteins
by PKCα, ERMs can act as downstream effector of PKC
to mediate cell migration when the later was stimulated
with phorbol-ester [51]. PKC activation by phorbol ester
also caused a switch in phosphorylation site of the
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transmembrane receptor CD44 from Ser325 to Ser29
and this phosphorylation regulated the association of
ezrin with CD44 to promote directional cell migration
triggered by CD44 [52]. Ezrin binds cell-neural adhesion
molecule (L1-CAM) to promote progression of colorec-
tal cancer in that RNA interference of ezrin activity
inhibited tumour metastasis mediated by L1-CAM [53].
In 3D matrigel matrix, perturbation of ezrin activity with
small hairpin RNA technology reduced the metastatic
and invasive capabilities of MDA-MB-231 and MCF10A
breast cancer cell lines [54]. Ezrin Y145 phosphorylation
in mouse mammary carcinoma cell line SP1 [55] and in
pig kidney epithelial LLC-PK1 [56] cells resulted in cell
spreading. Elevated expression of ezrin has been re-
ported in LTE, BE1, H446 and H460 lung cancer cell
lines, and a substantial decrease in migration, prolifera-
tion and invasion was observed upon siRNA-mediated
knockdown of ezrin [57]. In high grade prostate cancers,
overexpression of ezrin has been reported [58, 59], and
this was attributed to increased expression of oncogenic
c-Myc [60]. Interestingly, ezrin itself, through a feedback
loop involving the Akt/PI3K pathway can regulate c-
Myc levels and this is crucial for cell migration and inva-
sion [60, 61]. Ezrin overexpression has been shown in
other cancer such as pancreatic carcinoma, rhabdomyo-
sarcoma and osteosarcoma [62–64].
Radixin
Although, much is not known about the role of radixin
in cancer, unlike ezrin, however, radixin has been impli-
cated in prostate cancer progression [65]; and impair-
ment of radixin in human pancreatic cancer cell line by
shRNA not only significantly attenuated cell prolifera-
tion, survival, adhesion and invasion but also enhanced
expression levels of the cell-cell adhesion molecule, E-
cadherin [66]. In a manner dependent on Vav (a guanine
exchange nucleotide factor for Rac1) activity, downregu-
lation of radixin levels resulted in an increase in Rac1
activity [67]. In radixin, phosphorylation of a conserved
threonine 564 residue is sufficient to prevent the inter-
action of the FERM domain at the N-terminus with the
F-actin binding domain at the C-ERMAD terminus, and
this results in constitutive opening of the membrane and
F-actin binding domains [68]. Indeed, in Madin-Darby
canine kidney (MDCK) epithelial cells, phosphorylation
of radixin on this site (T564) by the G protein-coupled
receptor kinase 2 (GRK2) was able to induce membrane
protrusions as well as increased migration of the cells as
determined by wound healing assay [69]. In contrast to
the aforementioned positive roles of radixin in tumouri-
genesis, a novel role in which the protein appeared to in-
hibit metastasis has been reported. According to this
report, perturbation of radixin activity in the metastatic
prostate cancer cell line PC3 by siRNA technology
resulted in an elevated increase in spreading of cells, en-
hanced cell-cell adhesion and acquisition of epithelial
phenotype [70].
Moesin
Expression of moesin has been correlated with increased
tumour size and invasive capability, and there was an ab-
errant trafficking of the protein from plasma membrane
to the cytosol in oral squamous carcinoma cell (OSCC)
in which moesin was knocked down [71]. Similarly,
whereas high grade glioblastoma showed high expression
levels of moesin, there was no change in expression levels
of ezrin and radixin [72]. Moesin promoted tumour cell
invasion in that in vitro 3D cell migration assays revealed
that moesin depleted-cells exhibited reduced invasiveness
[61, 73]. Moesin is considered an important promoter of
metastasis as it has been shown to induce EMT in human
mammary cell MCF10A [74], and there are now emerging
reports that moesin is upregulated in different human
cancer cell lines [75, 76] as well as a marker of EMT [74,
77, 78]. In the same vein, high level of moesin was also
found in head and neck squamous cell carcinoma [79].
Whereas both moesin and radixin were found upregulated
in lymph node metastases of pancreatic cancer, the level
of ezrin expression was unaffected, but its phosphoryl-
ation status did change [80].
Conclusion and future perspectives
ERM proteins play very vital role in maintaining cellular
integrity and in mediating signal transduction from dif-
ferent extracellular inputs through their interaction dif-
ferent receptor tyrosine kinases (RTKs) such as EGFR
and HGFR, adhesion and adaptor proteins such as E-
cadherin, ICAM-1,2,3, NHERF and CD44, and other sig-
naling pathways such as PI3K/Akt, cAMP/PKA and the
Rho GTPases, all of which have been implicated in
tumorigenesis; thus, making ERM proteins important
target in development of novel therapeutics in fighting
cancer progression. Although, there are ample reports
on involvement of ERMs in cancer, detailed understand-
ing of the mechanisms of their interactions with other
proteins as well as their activation is still lacking and re-
quires further investigation.
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